Anti hbc

Manufactured by Abbott

Sourced in United States, Germany

The Anti-HBc is a laboratory test used to detect the presence of antibodies to the hepatitis B core antigen (HBcAg) in the blood. This test is used as a diagnostic tool to determine if a person has been exposed to and developed an immune response to the hepatitis B virus.

Automatically generated - may contain errors

Lab products found in correlation

Hbsag, by Abbott (4 mentions) Hbeag, by Abbott (4 mentions) Anti hbe, by Abbott (4 mentions) Architect system, by Abbott (2 mentions) Cobas taqman hbv test, by Roche (2 mentions) Anti hbs, by Abbott (2 mentions) Genscreen ultra hiv ag ab, by Bio-Rad (1 mentions) Determine hiv 1 2, by Abbott (1 mentions) Murex hiv ag ab combination, by DiaSorin (1 mentions) Cobas 6800 system, by Roche (1 mentions) Hiv ag ab combo, by Abbott (1 mentions) Anti hcv, by Abbott (1 mentions)

8 protocols using anti hbc

Quantitative assessment of hepatitis B

Check if the same lab product or an alternative is used in the 5 most similar protocols

The reagent kits of HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc were purchased from Abbott Laboratories in Chicago, IL, USA (HBsAg: Cat# 6C36, Lot No. 24052FN01; anti-HBs: Cat# 7C18, Lot No. 23294FN00; HBeAg: Cat# 6C32, Lot No. 23193BE01; anti-HBe: Cat# 6C34, Lot No. 24005BE01; anti-HBc: Cat# 6C33, Lot No. 24324BE01). Serum HBV DNA level was quantified using the HBV PCR Fluorescence Quantitative Detection Kit from Tianlong Bio-technology in Suzhou, China (Cat# 6C34, Lot No. P1372104001), with 500 IU/mL as the lower limit of detection. ALT was quantified using the Alanine Aminotransferase Test Kit from Ruiyuan Bio-technology in Ningbo, China (Cat# 1040-717, Lot No. 2020100902). CELLPACK DCL from Beckman-Coulter Experimental System in Suzhou, China (Cat# 628020, Lot No. 2010141) was used to test blood cell analysis, including the absolute value of lymphocytes, absolute values of monocytes and absolute values of neutrophils.

Zhang Q., Huang H., Sun A., Liu C., Wang Z., Shi F., Duan W., Sun X., Wang Q., Sun P., Pu C, & Zhang Y. (2021). Change of Cytokines in Chronic Hepatitis B Patients and HBeAg are Positively Correlated with HBV RNA, Based on Real-world Study. Journal of Clinical and Translational Hepatology, 10(3), 390-397.

+ Open protocol

+ Expand

HBV Serological Markers and Liver Function

Check if the same lab product or an alternative is used in the 5 most similar protocols

HBV serological markers were analysed with the Architect Abbott system (HBsAg, Anti-HBc, HBeAg, and Anti-HBe; Abbott Diagnostics, Wiesbaden, Germany). Liver function was evaluated by alanine aminotransferase test (ULN = 40 UI/l). Serum HBV DNA level was quantified by COBAS TaqMan HBV test (Roche Diagnostic Systems Inc., Mannheim, Germany). The dynamic range of quantification is 10 1 to 10 8 IU/ml.

Gauder C., Mojsiejczuk L.N., Tadey L., Mammana L., Bouzas M.B., Campos R.H, & Flichman D.M. (2019). Role of viral load in Hepatitis B virus evolution in persistently normal ALT chronically infected patients. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 67.

+ Open protocol

+ Expand

HBV Serological Markers and Liver Function

Check if the same lab product or an alternative is used in the 5 most similar protocols

Culasso A.C.A., Monzani M.C., Baré P, & Campos R.H. (2018). Evolutionary dynamics of Hepatitis C virus in a chronic HIV co-infected patient and its correlation with the immune status. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 63.

+ Open protocol

+ Expand

Comprehensive Viral Serological Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

The participants’ serum was tested using the Abbott ARCHITECT® automated immunologic assay platform and commercially available ARCHITECT assay kits for HCV antibody (anti-HCV) and HCV core antigen (HCVcoreAg), hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core antibodies (anti-HBc) (Abbott Laboratories, USA). Specimens were initially screened for anti-HCV and HBsAg and with subsequent testing of reactive specimens for HCVcoreAg and HBeAg, respectively. Each run included standardized ARCHITECT® controls.
Blood specimens were tested for HIV per national guidelines: screening for HIV antibody using Genscreen Ultra HIV Ag/Ab (Bio-Rad, USA) with confirmation of positive tests by Determine HIV-1/2 (Alere, Japan) and Murex HIV Ag/Ab Combination (DiaSorin, United Kingdom of Great Britain and Northern Ireland) testing. The National Reference Laboratory at NIHE conducted external quality assurance on a randomly selected 10% of HIV-negative and 5% of HIV-positive screening samples.

Le L.V., O’Connor S., Tran T.H., Maher L., Kaldor J., Sabin K., Tran H.V., Tran Q.D., Ho V.A, & Nguyen T.A. (2019). High hepatitis C virus infection among female sex workers in Viet Nam: strong correlation with HIV and injection drug use. Western Pacific Surveillance and Response Journal : WPSAR, 10(3), 9-18.

+ Open protocol

+ Expand

Serological and Molecular Screening for Viral Infections

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serological examinations for Human immunodeficiency virus (HIV), Hepatitis B virus (HBc), Hepatitis C virus (HCV) and Treponema pallidum exposure were performed on Alinity s analyzer using following Alinity s assays: HIV Ag/Ab Combo, Anti-HBc, Anti-HCV and Syphilis reagent kit (Abbott, North Chicago, IL, USA). Direct detection of Human immunodeficiency virus, Hepatitis B virus, Hepatitis C virus in blood samples was performed on Cobas 6800 System with Roche Cobas MPX kit (Roche Diagnostics International AG, Rotkreuz, Switzerland). All assays and appliances were used according to manufacturer instructions.

Grujić J., Bujandrić N., Budakov-Obradović Z., Dolinaj V., Bogdan D., Savić N., Cabezas-Cruz A., Mijatović D., Simin V., Anđelić N, & Banović P. (2021). Demographic and Clinical Factors Associated with Reactivity of Anti-SARS-CoV-2 Antibodies in Serbian Convalescent Plasma Donors. International Journal of Environmental Research and Public Health, 19(1), 42.

+ Open protocol

+ Expand

Quantitative Analysis of Hepatitis B Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

ALT and HBV markers [HBsAg, anti-HBs, HBV e antigen (HBeAg), anti-HBe and anti-HBc] were measured using a C1600 biochemical analyzer (Abbott Laboratories, Lake Bluff, IL, USA) and an i2000 immunoassay instrument (Abbott Laboratories), respectively. ALT (cat. no. GP6040) and HBV marker [HBsAg (cat. no. 6C36-32), anti-HBs (cat. no. 7C18-30), HBeAg (cat. no. 6C32-20), anti-HBe (cat. no. 6C34-20) and anti-HBc (cat. no. 8L44-30)] kits were purchased from Beijing Leadman Biochemistry Co., Ltd. (Beijing, China) and Abbott Laboratories, respectively. The linear range of HBsAg was between 0.05 and 250 IU/ml. If the HBsAg level was >250.0 IU/ml, the samples were serially diluted 1:100 to obtain a value within the linear range of the assay, according to the manufacturer's protocol.

Wang T., Dai Y., Zhang M., Cui D., Xu X., Sun C, & Cheng J. (2018). Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg. International Journal of Molecular Medicine, 42(5), 2689-2699.

+ Open protocol

+ Expand

Hepatitis B and Delta Virus Serosurvey

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dried blood spots were examined as described previously [18 (link)]. All three markers HBsAg, anti-HBc and anti-HBs tests (Abbott-Murex, United Kingdom) were performed according to the manufacturers’ instructions in 2160 individuals’samples. HBsAg-positive results were confirmed in the Murex HBsAg Confirmatory test, Version 3. HBsAg-positive samples from the 1985 (n = 84) and 2010 (n = 181) serum collections were screened for HDV with the anti-HDV total antibody test and HDAg detection tests (diaSorin, Italy).

Komas N.P., Ghosh S., Abdou-Chekaraou M., Pradat P., Al Hawajri N., Manirakiza A., Laghoe G.L., Bekondi C., Brichler S., Ouavéné J.O., Sépou A., Yambiyo B.M., Gody J.C., Fikouma V., Gerber A., Abeywickrama Samarakoon N., Alfaiate D., Scholtès C., Martel N., Le Gal F., Lo Pinto H., Amri I., Hantz O., Durantel D., Lesbordes J.L., Gordien E., Merle P., Drugan T., Trépo C., Zoulim F., Cortay J.C., Kay A.C, & Dény P. (2018). Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. PLoS Neglected Tropical Diseases, 12(4), e0006377.

+ Open protocol

+ Expand

Hepatocellular Carcinoma and Chronic Liver Disease Serology

Check if the same lab product or an alternative is used in the 5 most similar protocols

We conducted a nested case-control study of HCC and CLD deaths within the biospecimen subcohort for serological markers of hepatitis B and C infection in blood samples of 210 cases (137 HCC cases and 73 CLD deaths) and 423 controls. All incident cases of HCC and CLD deaths with a pre-diagnostic blood sample were eligible for this case-control study. For each case, two control subjects matched to the index case by sex, race/ethnicity, study area (Hawaii or California), and age at blood draw, were selected from the biospecimen subcohort. Controls also had to be free of HCC on the date of cancer diagnosis or CLD death of the index case. The presence of HBsAg, anti-HBc, and anti-HCV (Architect Assays, Abbott Laboratories, North Chicago, IL) were tested blindly without regard to case-control status.

Setiawan V.W., Wilkens L.R., Lu S.C., Hernandez B.Y., Le Marchand L, & Henderson B.E. (2014). Association of Coffee Intake with Reduced Incidence of Liver Cancer and Death from Chronic Liver Disease in the US Multiethnic Cohort. Gastroenterology, 148(1), 118-125.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!